参考文献:(滑动查看)
1、中国抗癌协会国际医疗与交流分会,中国医师协会肿瘤医师分会乳腺癌学组.人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版).中华肿瘤杂志,2022,44(12):1288-1295.DOI:10.3760/cma.j.cn112152-20220914-00623
2、Slamon DJ,Clark GM,Wong SG,et al;Human breast cancer:Correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235:177-182,1987
3、Slamon DJ,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med.2001 Mar 15;344(11):783-92.
4、Baselga J,Bradbury I,Eidtmann H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised,open-label,multicentre,phase 3 trial.Lancet.2012;379:633–40.
5、Geyer CE,et al.Lapatinib plus Capecitabine for HER2-Positive Advanced BreastCancer.N Engl J Med.2006 Dec 28;355(26):2733-43.
6、Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2 positive advanced breast cancer.N Engl J Med,2012,367(19):1783-1791.
7、Krop IE,Kim S-B,González-Martín A,et al.Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial.Lancet Oncol.2014;15(7):689–699.
8、Hurvitz Sara A,Hegg Roberto,Chung Wei-Pang,et al.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer:updated results from DESTINY-Breast03,a randomised,open-label,phase 3 trial.[J].Lancet,2023,401:105-117.
9、Louis Fehrenbacher et al.J Clin Oncol.2020 Feb 10;38(5):444-453
10、Michael F Press et al.Clin Cancer Res.2008 Dec 1;14(23):7861-70.
11、Luca Gianni et al.J Clin Oncol.2010 Mar 1;28(7):1131-7.
12、Howard A Burris 3rd et al.J Clin Oncol.2011 Feb 1;29(4):398-405;Ian E Krop et al.J Clin Oncol.2012 Sep 10;30(26):3234-41.
13、NAKADA T,SUGIHARA K,JIKOH T,et al.The latest research and development into the antibody-drug conjugate,[fam-]trastuzumab deruxtecan(DS-8201a),for HER2 cancer therapy[J].Chem Pharm Bull,2019,67(3):173-185.
14、Doi T,Shitara K,Naito Y,et al.Safety,pharmacokinetics,and antitumour activity of trastuzumab deruxtecan(DS-8201),a HER2-targeting antibody-drug conjugate,in patients with advanced breast and gastric or gastro-oesophageal tumours:a phase 1 dose-escalation study.Lancet Oncol.2017 Nov;18(11):1512-1522
15、Mosele F,Deluche E,Lusque A,et al.Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression:the phase 2 DAISY trial.Nat Med.2023;29(8):2110-2120.
16、Nakada T,et al.Chem Pharm Bull.2019;67:173-85.Ogitani Y,et al.Clin Cancer Res.2016;22:5097-108.Modi S,et al.J Clin Oncol 2020;38:1887-96.
17、Modi,Shanu et al.“Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.”The New England journal of medicine vol.387,1(2022):9-20.doi:10.1056/NEJMoa2203690
18、Huina Zhang,Yan Peng Cancers(Basel).2022 Dec 25;15(1):126.
19、Shanu Modi,et al.Trastuzumab deruxtecan(T-DXd)vs treatment of physician’s choice(TPC)in patients(pts)with HER2-low,hormone receptor-positive(HR+)unresectable and/or metastatic breastcancer(mBC):Exploratory biomarker analysis of DESTINY-Breast04.2023 ASCO Abstract1020.
20、https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer
21、https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230713154938169.html